Argentina Labeling Requirements: The Nine Label Elements under Annex IV

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The Argentine requirements for labels and IFUs are based on Annex IV of GMC 25/21 (the updated successor to Annex III.B of Disposición ANMAT 2318/2002), and the label must be in Spanish. The label must state at least the following 9 items:

  1. The legal names and complete addresses of the manufacturer and the importer (registration holder) — where the country of manufacture differs from the country of the holder’s legal entity, the country of origin must be indicated;
  2. The registration number (with the identifying abbreviation of the competent authority as prefix);
  3. The batch number (with the word “lote”) or the serial number;
  4. The date of manufacture and the expiry date or use-by date;
  5. The “estéril” (sterile) marking, where applicable;
  6. The single-use marking, where applicable;
  7. Storage and transport conditions;
  8. The sterilization method, where applicable;
  9. The name of the technical director.

Information necessary for safe use must be presented in a clearly legible manner, and the presentation of these elements should be treated as a design constraint on the artwork rather than an afterthought once the artwork is complete.

It is worth noting how this element list differs from the labeling regimes of other major markets. Items such as the technical director and the domestic registration number with its competent-authority prefix are Argentine-specific, and artwork templates imported from other jurisdictions will not contain them. The efficient approach is to build a single Argentine master artwork template containing all nine elements, with variant fields for the products in the portfolio, so each new product inherits a compliant baseline instead of re-deriving one.

2. Legal basis

Regulatory instrumentNumberPublication dateRelevant provisions
MERCOSUR technical regulation for medical device registrationGMC/RES 25/21October 13, 2021Annex IV (label and IFU requirements)
Domestic implementing instrumentDisposición ANMAT 64/2025Published in the Official Gazette on January 13, 2025Labeling requirement provisions
IVD labeling requirementsDisposición ANMAT 2674/991999Supplementary IVD labeling provisions
Repealed: former labeling requirementsDisposición ANMAT 2318/2002, Annex III.B2002Superseded by Annex IV of GMC 25/21

The row for the repealed instrument is a useful reminder of how the framework evolved. Annex III.B of Disposición ANMAT 2318/2002 was the former home of the labeling rules, and Annex IV of GMC 25/21 now supersedes it, which means any internal procedure still citing the 2002 annex should be updated to cite the current MERCOSUR annex. Labeling checklists that survive from the old regime are exactly where stale citations hide.

3. Expert insights

Insight 1: the registration number is the one label element that cannot be filled in before the certificate exists. This forces a two-step label finalization: at submission, a label artwork is filed with a placeholder for the registration number, and after the certificate is granted the PM registration number is inserted and the artwork is finalized for printing. A company that prints labels bearing a registration number too early risks scrapping the entire batch if the number changes, so holding the print run until the certificate is in hand is the only safe sequencing.

Insight 2: the name of the technical director is an Argentine-specific element. That name must match the Director Técnico registered by the holder with ANMAT. When the holder replaces the technical director, the name on the label must be updated in step, which is an easily overlooked change trigger: the change is internal to the holder, yet it propagates all the way onto the printed packaging.

Insight 3: kits enjoy an exemption, but their requirements are not reduced. A kit composed of already registered products in their original intact packaging may be exempted from combined registration, yet the label and IFU must still state the registration information of each component. What is exempted is the registration action, not the labeling obligation, and drafting kit artwork on the assumption that the exemption carries further will fail review.

4. Practical recommendations

  1. Build the label checklist around the nine elements. Tick them one by one, with special attention to the three items most often missed: the country-of-origin indication, the batch prefix “lote”, and the name of the technical director.
  2. Manage the label in two versions. Archive the submission version (registration number placeholder) and the post-grant version (PM registration number inserted) separately, and start printing only after the certificate is granted.
  3. Create a linkage mechanism between technical director changes and label updates. When the holder replaces the technical director, trigger a label update and an assessment of whether a notifiable change arises, so the artwork and the ANMAT record never diverge.
  4. Layer Disposición 2674/99 onto IVD labels. In vitro diagnostic products must satisfy Annex IV and Disposición 2674/99 simultaneously, and the design review should check both instruments rather than assuming the general checklist is sufficient.

5. Verification checklist

  • □ Label and IFU both in Spanish
  • □ Legal names and complete addresses of manufacturer and importer stated
  • □ Country of origin indicated where the manufacturing country differs from the holder’s country
  • □ Batch number (with the word “lote”) or serial number marked
  • □ Date of manufacture and expiry or use-by date marked
  • □ Applicable items marked: sterile, single-use, sterilization method, storage and transport conditions
  • □ Name of the technical director consistent with the ANMAT record
  • □ IVD label additionally satisfies Disposición 2674/99

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can serve as the registration holder and importer of record for foreign manufacturers, directly handling classification assessment, pathway selection, building the GMP and CFS documentation chain, Spanish-language localization of technical documentation and labeling, HELENA submissions and responses to deficiency letters, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and planning for the 5-year renewal. For support with registration dossiers and conformity documentation for the Argentine market, contact the GRZAN regulatory team at info@grzanglobal.com.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in international registrations, tracks the activity of regulatory authorities across markets on an ongoing basis, and applies a writing standard of conclusions first, traceable sources and verifiable figures to everything it publishes. For a market access plan tailored to a specific product in Argentina or the wider MERCOSUR region, the GRZAN regulatory team welcomes your enquiry at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail